Johnson & Johnson Stock News

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCELONA, Spain , Sept. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of ...

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results  show potential of RYBREVANT® beyond lung cancer BARCELONA , Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOL...

Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy alone BARCELONA , Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outco...

Ongoing lawsuits have presented the opportunity. It is up to the investor to decide just how much risk this adds to the thesis. Post Kenvue spin, the company is deciding to use cash to further diversify their MedTech offerings. The great thing about MedTech versus increasing investment in Medicines is that they don't face the same "patent cliff" issues.

Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies

The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with a type of chronic inflammatory bowel disease, the company said on Wednesday.

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ®  showed  highly s tatistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5 TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis HORSHAM, Pa. , Sept. 11, 2024 /PRNewswire/ -- Johnson ...

The stock market can feel like a roller coaster, especially during economic uncertainty. As fears of a recession increase, investors seek stability and look for investments that can weather the storm and offer a sense of security.